Kuleon Bioscience
Preclinical1 active candidate
same indication: Alcohol Use Disorder (AUD)Preclinical peersame regulator: US FDAsimilar active pipeline size
Back to StakeholdersProgramme tracker View landscape
Lead program: Preclinical
Journey Colab
CategoriesEarly-Stage Translational Research (Pre-Clinical)Research, Drug Development & Manufacturing
Data updated
1 Drug Candidate
Enterprise Intelligence
Quarterly psychedelic drug-development briefing
Compare indication activity, programme milestones, competitive intensity, and near-term catalysts. Q2 includes quarter-over-quarter changes against the published Q1 baseline.
Journey Colab is a US psychedelic pharmaceutical company developing synthetic mescaline hydrochloride for alcohol use disorder (AUD). Founded in 2020, the company has raised $30.7M from investors including Sam Altman, Apollo Projects, and Drew Houston. Journey Colab has dedicated 10% of its founding equity to a Reciprocity Trust supporting Indigenous communities from which mescaline knowledge originates. The company is partnering with All Points North (APN) for an FDA-authorised Phase 2 clinical trial.
Ecosystem
8 connectionsInvestors
Apollo Projects
Initial investment
Oct 26, 2020
$3 million
Journey Colab bags $3M from 'moonshot' fund to push new development model for psychedelicSeed
Oct 26, 2020
$3 million
Journey Colab bags $3M from 'moonshot' fund to push new development model for psychedelic treatmentsMBX CapitalMBX Capital | Deep Health VC
Partnered
Jan 1, 2021
Philanthropic Funders
Journey Colab Reciprocity TrustJourney Colab Reciprocity page
Reciprocity trust launch and commitment framework
Pipeline Intelligence
Developer Momentum
- Active candidates
- 1
- Active programmes
- 1
- Lead stage
- Preclinical
- Forecast coverage
- 1 of 1
All tracked candidates active
All tracked programmes active
Current furthest stage
1 active programme with forecast fields
Latest sourced update
Mescaline HCl - Journey Colab
Jun 26, 2026 - drug-database - AdisInsight - JOUR-5700 (Synthetic Mescaline HCl)
Next known catalyst
Phase I started
Timing not specified - JOUR-5700 (Synthetic Mescaline HCl) / JOUR-5700 Programme (AUD) — Pre-Phase 1 - Confidence: 30%
5 sources0 pipeline-linked trials0 pipeline-linked papers
Development Programmes
1JOUR-5700 (Synthetic Mescaline HCl)
MescalinePreclinical
Alcohol use disorder
Alcohol Use Disorder (AUD)
Primary: US (FDA)
Pre-clinicalActive
Forecast
Phase I started
JOUR-5700 remains a preclinical mescaline HCl AUD programme in public databases and historical company coverage; no ClinicalTrials.gov registration or recent Journey Colab clinical-start update was found in this pass.
Milestones
Funding milestone
CompletedActual: Jan 1, 2020
Founded by Dr Jeeshan Chowdhury and Jennifer Pisansky; $3M seed from Apollo Projects (Sam Altman's moonshot fund)
Why it matters: First company to pursue synthetic mescaline through FDA clinical development. Apollo Projects backing (Sam Altman) signals Silicon Valley interest in psychedelic medicine for addiction.
Funding milestone
CompletedActual: Oct 1, 2022
$12M Series A raised (total $15M); preclinical and CMC programmes completed
Why it matters: Well-capitalized for Phase 1 entry. Preclinical and chemistry/manufacturing/controls completion means JOUR-5700 is Phase 1-ready from a drug development perspective.
Company milestone
CompletedActual: Oct 1, 2022
Nature profile published on mescaline clinical development and Journey Colab's approach
Why it matters: Nature coverage validates the scientific rationale for mescaline in AUD. Mescaline is the only classical psychedelic with no modern clinical trial data — it was studied extensively in the 1950s-60s for alcoholism but never progressed through modern regulatory frameworks.
Company milestone
CompletedActual: Dec 1, 2023
Last known public activity — no press releases, no NCT registered, no trial recruitment announced since late 2023
Why it matters: Phase 1 at CHDR was expected to begin by 2023 but appears not to have started. Over 2 years of silence is concerning. Company is still listed as active on PitchBook/Crunchbase with $15M total raised. May be in stealth-mode development or facing funding/regulatory challenges.
Watch next: Phase 1 trial registration on ClinicalTrials.gov; CHDR site activation; any press release or funding announcement
Recorded Events
Dec 1, 2023: Company milestone
Oct 1, 2022: Funding milestone
Oct 1, 2022: Company milestone
Jan 1, 2020: Funding milestone
Evidence Links
Mescaline HCl - Journey Colab
drug-database - AdisInsight - Jun 26, 2026 - Verified
Drug profile identifies JOUR-5700 synthetic mescaline HCl as Journey Colab preclinical AUD candidate.
Journey Colab Scores 12M to Move Addiction Treatment Toward Clinic
industry-media - Fierce Biotech - Sep 7, 2021 - Verified
Series A coverage describes Journey Colab plan to move a mescaline-based AUD programme toward first human testing.
From Cultural Rite to Clinical Trial - Mescaline Potential
industry-media - QPS - Nov 28, 2022 - Verified
QPS article describes JOUR-5700 as synthetic mescaline being developed for AUD and planned ascending-dose study.
Similar Developers
Reference points selected from shared pipeline stage, indications, compounds, regulatory pathways, and evidence footprint.
Tactogen
Preclinical2 active candidates
same indication: Alcohol Use Disorder (AUD)Preclinical peersame regulator: US FDAsimilar active pipeline size
Psilera
Preclinical3 active candidates1 paper
same indication: Alcohol Use Disorder (AUD)Preclinical peersame regulator: US FDAboth have forecast coverage
Biomind Labs
Phase II2 active candidates3 trials
shared compound: Mescalinesame regulator: US FDAsimilar active pipeline sizeboth have forecast coverage
Quick Facts
- Type
- Private Biotech
- Founded
- 2020
- Lead Stage
- Preclinical
- Website
- Visit